Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2594017 | 1.00 | NAPRT (0.52) | NAPRTHTTGAAMAPTHPGD | |
| SCHEMBL2594019 | 1.00 | NAPRT (0.52) | NAPRTHTTGAAMAPTHPGD | |
| SCHEMBL10984963 | 0.80 | NFE2L2 (0.64) | NAPRTGAAMAPTHPGDLMNA | |
| SCHEMBL10984957 | 0.80 | NFE2L2 (0.64) | NAPRTGAAMAPTHPGDLMNA | |
| SCHEMBL3309518 | 0.79 | NAPRT (0.52) | NAPRTHTTGAAMAPTHPGD | |
| SCHEMBL3309520 | 0.79 | NAPRT (0.52) | NAPRTHTTGAAMAPTHPGD | |
| SCHEMBL3309513 | 0.79 | NAPRT (0.52) | NAPRTHTTGAAMAPTHPGD | |
| SCHEMBL11013553 | 0.79 | CYP1A2 (0.60) | NAPRTHTTGAAMAPTHPGD | |
| SCHEMBL11013551 | 0.79 | CYP1A2 (0.60) | NAPRTHTTGAAMAPTHPGD | |
| SCHEMBL29423291 | 0.78 | NFE2L2 (0.61) | NAPRTGAAMAPTHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10478426-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180207144-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2018-07-26 | — | — | US | disclosed |
| US-9956210-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-05-01 | — | — | US | disclosed |
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-20170095461-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2017-04-06 | — | — | US | disclosed |
| US-9562041-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| EP-2646020-B1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2016-09-21 | — | — | EP | disclosed |
| US-9446041-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20130245016-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-09-19 | — | — | US | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2013067296-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067300-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| EP-2566328-A1 | INDAZOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| EP-2566327-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2011140325-A1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245016-A1 | INDOLES | IDO1, IDO2, INMT | NAPRT 1052/4885HTT 3255/4885GAA 3880/4885 |
| US-20130053383-A1 | INDAZOLES | IDH3A, CYP3A7, IDH3B | NAPRT 1238/4885HTT 4831/4885GAA 1575/4885 |
| US-20180207144-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, EZH1, BMI1 | NAPRT 3464/4885HTT 4426/4885GAA 1965/4885 |
| US-20170095461-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, EZH1, BMI1 | NAPRT 3464/4885HTT 4426/4885GAA 1965/4885 |
| US-10478426-B2 | Enhancer of Zeste Homolog 2 inhibitors | EZH2, EZH1, BMI1 | NAPRT 3464/4885HTT 4426/4885GAA 1965/4885 |
| US-20130053397-A1 | INDOLES | IDO1, IDO2, INMT | NAPRT 1046/4885HTT 3415/4885GAA 3907/4885 |
| US-20160296518-A1 | INDOLES | IDO1, IDO2, INMT | NAPRT 1052/4885HTT 3255/4885GAA 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.